Related Experiment Video
Updated: Jun 5, 2025

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
Published on: August 2, 2018
Management of Cardiac Involvement in Becker Muscular Dystrophy: A Case Report
Taulant Gishto1, Silvia Methoxha1, Naltin Shuka2
1Cardiovascular Disease, University Hospital Center "Mother Teresa", Tirana, ALB.
Abstract:
Becker muscular dystrophy (BMD) is an X-linked recessive neuromuscular disorder caused by a mutation in the dystrophin gene. Cardiac involvement is a frequent finding in BMD, and manifestations may vary from asymptomatic cardiac involvement to developing symptoms of heart failure and severe cardiomyopathy. We presented the case of a 32-year-old wheelchair-dependent BMD patient who came to our cardiology clinic with a two-month history of heart palpitations, rest and nocturnal dyspnea, fatigue, and generalized muscular weakness. Upon evaluation, a 24-hour Holter rhythm showed complex ventricular arrhythmia and 300 polymorphic ventricular extrasystoles with episodes of ventricular bigeminy, while echocardiography revealed a dilated left ventricle with severe systolic dysfunction (left ventricular ejection fraction (LVEF) 23%) and impaired global contractility. An implantable cardioverter defibrillator (ICD) was implanted, and guideline direct medical therapy (GDMT), sacubitril/valsartan, bisoprolol, furosemide, spironolactone, and dapagliflozin were initiated. The patient was discharged five days later, in an improved clinical condition, without dyspnea. A follow-up appointment two weeks after discharge was recommended in order to evaluate the patient's symptoms and the effectiveness of GDMT and a follow-up echocardiography at least three months after discharge to evaluate the heart's systolic and diastolic function.
More Related Videos
08:13Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
09:18Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Related Concept Videos
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Myocarditis IV: Nursing Management
Satellite Stem Cells and Muscular Dystrophy
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Mitral Valve Prolapse II: Assessment and Management